All Stories

  1. Validation of ICD-10 codes used to identify the main reason for hospitalization due to hyponatremia in Sweden

    Article • PLOS One, February 2025, PLOS

    PhD Jan Calissendorff

  2. Sex differences in presentation of pheochromocytoma and paraganglioma

    Article • Frontiers in Endocrinology, January 2025, Frontiers

    PhD Jan Calissendorff

  3. Renal pseudohypoaldosteronism type 1—an adult case series including a novel gene variant

    Article • Endocrine, November 2024, Springer Science + Business Media

    PhD Jan Calissendorff

  4. Surgical outcome after thyroidectomy due to Graves’ disease and Lugol iodine treatment: a retrospective register-based cohort study

    Article • Endocrine, February 2024, Springer Science + Business Media

    Henrik Falhammar, PhD Jan Calissendorff

  5. The dangerous trend of levothyroxine medicalization

    Article • Trends in Endocrinology and Metabolism, December 2023, Elsevier

    PhD Jan Calissendorff

  6. A prospective study on a short course of lugol's solution in toxic nodular goiter

    Article • Endocrine Abstracts, August 2023, Bioscientifica

    PhD Jan Calissendorff

  7. Adrenal cysts: an emerging condition

    Article • Nature Reviews Endocrinology, April 2023, Springer Science + Business Media

    Henrik Falhammar, PhD Jan Calissendorff

  8. Radioiodine treatment outcome by dosimetric parameters and renal function in hyperthyroidism

    Article • Thyroid Research, April 2022, Springer Science + Business Media

    PhD Jan Calissendorff

  9. Pheochromocytomas and Abdominal Paragangliomas: A Practical Guidance

    Article • Cancers, February 2022, MDPI AG

    Henrik Falhammar, PhD Jan Calissendorff

  10. Thyrotoxic Periodic Paralysis: A Review and Suggestions for Treatment

    Article • January 2022, Elsevier

    PhD Jan Calissendorff

  11. Metastasis to the thyroid gland: Characterization and survival of an institutional series spanning 28 years

    Article • European Journal of Surgical Oncology, June 2021, Elsevier

    Henrik Falhammar, PhD Jan Calissendorff

  12. Characteristics, Treatment, Outcomes, and Survival in Neuroendocrine G1 and G2 Pancreatic Tumors: Experiences From a Single Tertiary Referral Center

    Article • Frontiers in Endocrinology, April 2021, Frontiers

    PhD Jan Calissendorff

  13. To Treat or Not to Treat Subclinical Hypothyroidism, What Is the Evidence?

    Article • Medicina, January 2020, MDPI AG

    Henrik Falhammar, PhD Jan Calissendorff

  14. Acute suppurative thyroiditis with thyroid abscess in adults: clinical presentation, treatment and outcomes

    Article • BMC Endocrine Disorders, December 2019, Springer Science + Business Media

    Henrik Falhammar, PhD Jan Calissendorff

  15. Acute suppurative thyroiditis with thyroid abscess in adults: clinical presentation, treatment and outcomes

    Article • November 2019, Research Square

    Henrik Falhammar, PhD Jan Calissendorff

  16. Acute suppurative thyroiditis with thyroid abscess in adults: clinical presentation, treatment and outcomes

    Article • September 2019, Research Square

    Henrik Falhammar, PhD Jan Calissendorff

  17. Three Sisters With Heterozygous Gene Variants of CYP24A1: Maternal Hypercalcemia, New-Onset Hypertension, and Neonatal Hypoglycemia

    Article • Journal of the Endocrine Society, December 2018, Endocrine Society

    PhD Jan Calissendorff

  18. Differences in associations of antiepileptic drugs and hospitalization due to hyponatremia: A population–based case–control study

    Article • Seizure, July 2018, Elsevier

    PhD Jan Calissendorff, Henrik Falhammar

  19. Riedel’s thyroiditis: clinical presentation, treatment and outcomes

    Article • Endocrine, January 2018, Springer Science + Business Media

    PhD Jan Calissendorff, Henrik Falhammar

  20. Differences in Associations of Antidepressants and Hospitalization Due to Hyponatremia

    Article • The American Journal of Medicine, January 2018, Elsevier

    PhD Jan Calissendorff, Henrik Falhammar

  21. Initial clinical presentation and spectrum of pheochromocytoma: a study of 94 cases from a single center

    Article • Endocrine Connections, December 2017, Bioscientifica

    PhD Jan Calissendorff, Henrik Falhammar

  22. Lugol’s solution and other iodide preparations: perspectives and research directions in Graves’ disease

    Article • Endocrine, October 2017, Springer Science + Business Media

    PhD Jan Calissendorff, Henrik Falhammar

  23. Rescue pre-operative treatment with Lugol’s solution in uncontrolled Graves’ disease

    Article • Endocrine Connections, March 2017, Bioscientifica

    PhD Jan Calissendorff, Henrik Falhammar

  24. The relationship between thyroid hormone levels and cognitive functions in Graves’ disease might be influenced by a history of mild traumatic brain injury

    Article • January 2017, Open Access Text Pvt, Ltd.

    PhD Jan Calissendorff

  25. Frequency of Cushing’s syndrome due to ACTH-secreting adrenal medullary lesions: a retrospective study over 10 years from a single center

    Article • Endocrine, October 2016, Springer Science + Business Media

    PhD Jan Calissendorff, Henrik Falhammar

  26. Adrenocortical cancer: mortality, hormone secretion, proliferation and urine steroids – experience from a single centre spanning three decades

    Article • BMC Endocrine Disorders, March 2016, Springer Science + Business Media

    PhD Jan Calissendorff, Henrik Falhammar

  27. Adjuvant Treatment of Graves' Disease with Diclofenac: Safety, Effects on Ophthalmopathy and Antibody Concentrations

    Article • European Thyroid Journal, February 2016, Karger Publishers

    PhD Jan Calissendorff

  28. A Prospective Investigation of Graves' Disease and Selenium: Thyroid Hormones, Auto-Antibodies and Self-Rated Symptoms

    Article • European Thyroid Journal, May 2015, Karger Publishers

    PhD Jan Calissendorff

  29. Limited value of long-term biochemical follow-up in patients with adrenal incidentalomas-a retrospective cohort study

    Article • BMC Endocrine Disorders, February 2015, Springer Science + Business Media

    PhD Jan Calissendorff, Henrik Falhammar

  30. Primary aldosteronism: functional histopathology and long-term follow-up after unilateral adrenalectomy

    Article • Clinical Endocrinology, December 2014, Wiley

    PhD Jan Calissendorff

  31. Ileal neuroendocrine tumors and heart: not only valvular consequences

    Article • Endocrine, October 2014, Springer Science + Business Media

    PhD Jan Calissendorff, Henrik Falhammar

  32. High rates of fatigue in newly diagnosed Graves' disease

    Article • Fatigue Biomedicine Health & Behavior, July 2014, Taylor & Francis

    PhD Jan Calissendorff

  33. 68Ga-DOTA-TOC-PET/CT detects heart metastases from ileal neuroendocrine tumors

    Article • Endocrine, November 2013, Springer Science + Business Media

    PhD Jan Calissendorff, Henrik Falhammar

  34. Randomized crossover study in patients with neuroendocrine tumors to assess patient preference for lanreotide Autogel® given by either self/partner or a health care professional

    Article • Patient Preference and Adherence, October 2012, Dove Medical Press

    Associate Professor Dan Granberg, PhD Jan Calissendorff, Clinical Chair Professor Henning Gronbaek

  35. Thyrotoxic periodic paralysis: clinical and molecular aspects

    Article • Endocrine, August 2012, Springer Science + Business Media

    PhD Jan Calissendorff, Henrik Falhammar

  36. Antibodies to citrullinated protein antigen are not biomarkers for Grave's ophalmopathy

    Article • Clinical Endocrinology, July 2012, Wiley

    PhD Jan Calissendorff

  37. Alcohol Intake and Its Effect on Some Appetite-Regulating Hormones in Man: Influence of Gastroprotection with Sucralfate

    Article • Endocrine Research, May 2012, Informa Healthcare

    PhD Jan Calissendorff

  38. Incidence of hyperthyroidism in Sweden

    Article • European Journal of Endocrinology, September 2011, Bioscientifica

    PhD Jan Calissendorff

  39. Thyroxin substitution and open-angle glaucoma: a nationwide register-based study on filled prescriptions

    Article • British Journal of Ophthalmology, January 2011, BMJ

    PhD Jan Calissendorff

  40. Thyroid-associated ophthalmopathy; quality of life follow-up of patients randomized to treatment with antithyroid drugs or radioiodine

    Article • European Journal of Endocrinology, July 2010, Bioscientifica

    PhD Jan Calissendorff

  41. Thyroid-Associated Ophthalmopathy after Treatment for Graves’ Hyperthyroidism with Antithyroid Drugs or Iodine-131

    Article • The Journal of Clinical Endocrinology & Metabolism, October 2009, Endocrine Society

    PhD Jan Calissendorff

  42. Incidence of hyperthyroidism in Stockholm, Sweden, 2003-2005.

    Article • European Journal of Endocrinology, May 2008, Bioscientifica

    PhD Jan Calissendorff

  43. Alcohol-Induced Disruption of Endocrine Signaling

    Article • Alcoholism Clinical and Experimental Research, August 2007, Wiley

    PhD Jan Calissendorff

  44. Alcohol ingestion does not affect serum levels of peptide YY but decreases both total and octanoylated ghrelin levels in healthy subjects

    Article • Metabolism, December 2006, Elsevier

    PhD Jan Calissendorff

  45. Graves' Disease: A Long-Term Quality-of-Life Follow Up of Patients Randomized to Treatment with Antithyroid Drugs, Radioiodine, or Surgery

    Article • Thyroid, November 2005, Mary Ann Liebert Inc

    PhD Jan Calissendorff

  46. Inhibitory effect of alcohol on ghrelin secretion in normal man

    Article • European Journal of Endocrinology, May 2005, Bioscientifica

    PhD Jan Calissendorff

  47. Hunger–Satiety Signals in Patients with Graves' Thyrotoxicosis Before, During, and After Long-Term Pharmacological Treatment

    Article • Endocrine, January 2005, Springer Science + Business Media

    PhD Jan Calissendorff

  48. IS DECREASED LEPTIN SECRETION AFTER ALCOHOL INGESTION CATECHOLAMINE-MEDIATED?

    Article • Alcohol and Alcoholism, July 2004, Oxford University Press (OUP)

    PhD Jan Calissendorff

  49. Alcohol ingestion decreases both diurnal and nocturnal secretion of leptin in healthy individuals

    Article • Clinical Endocrinology, November 2001, Wiley

    PhD Jan Calissendorff